220 related articles for article (PubMed ID: 24504842)
21. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
23. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
24. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
[TBL] [Abstract][Full Text] [Related]
25. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.
Demir L; Yigit S; Ellidokuz H; Erten C; Somali I; Kucukzeybek Y; Alacacioglu A; Cokmert S; Can A; Akyol M; Dirican A; Bayoglu V; Sari AA; Tarhan MO
Clin Exp Metastasis; 2013 Dec; 30(8):1047-62. PubMed ID: 23836289
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
28. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
29. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
30. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
32. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors and Survival Outcomes among Patients with Breast Cancer and Brain Metastases at Diagnosis: A National Cancer Database Analysis.
Zimmerman BS; Seidman D; Cascetta KP; Ru M; Moshier E; Tiersten A
Oncology; 2021; 99(5):280-291. PubMed ID: 33652435
[TBL] [Abstract][Full Text] [Related]
34. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
35. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
Klar N; Rosenzweig M; Diergaarde B; Brufsky A
Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
[TBL] [Abstract][Full Text] [Related]
36. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
37. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
38. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
39. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.
Caldarella A; Crocetti E; Bianchi S; Vezzosi V; Urso C; Biancalani M; Zappa M
Pathol Oncol Res; 2011 Sep; 17(3):753-8. PubMed ID: 21479875
[TBL] [Abstract][Full Text] [Related]
40. Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer.
Bachmann C; Grischke EM; Staebler A; Schittenhelm J; Wallwiener D
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1909-16. PubMed ID: 24037487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
